Gilad Oren 4

What Happened

• Gilad Oren, President, CEO and Director of Aprea Therapeutics, was granted a total of 100,875 awards on March 12, 2026: 20,175 restricted stock units (RSUs) and 80,700 derivative awards (reported at $0.00 per share). The grants show $0 cash paid at grant; total reported acquisition value is $0.
• Vesting: the 20,175 RSUs vest in three equal annual installments beginning March 12, 2027 (F1). The 80,700 derivative awards vest 25% on March 12, 2027 with the remainder vesting ratably over the following 36 months (F3). All vesting is subject to continued employment and possible acceleration under certain conditions. The filing also includes a disclaimer that the reporting person disclaims beneficial ownership of these securities (F2).

Key Details

• Transaction date: March 12, 2026; Filing date: March 16, 2026 (filed within SEC two-business-day window).
• Price: $0.00 per share for both line items; reported acquisition value $0.
• Total awards granted: 100,875 (20,175 RSUs + 80,700 derivative awards).
• Shares owned after transaction: not disclosed in the provided filing details.
• Footnotes of note: F1 (RSU vesting schedule), F3 (derivative/options vesting schedule), F2 (disclaimer of beneficial ownership).
• Transaction type codes: A = Award/Grant; one line reported as derivative (likely option-type award) — both are time‑based with vesting conditions.

Context

• These are equity awards, not open-market purchases or sales, so they do not represent immediate buying or selling in the market. RSUs will convert to actual shares only as they vest and are settled.
• Grants at $0 purchase price are common for executive compensation; vesting conditions (continued employment, possible acceleration) determine when shares become owned and tradable.
• No cash proceeds or sales were reported; this is an issuance/compensation event rather than insider buying or selling.